Evidence map›Paper›PMID 40935955›Full record

ReviewClinical reviews in allergy & immunology2025

The Ubiquitin-Proteasome System in Asthma: Mechanisms and Therapeutic Possibilities.

Shuangyu He, Siqi Wen, Zhen Wang, Yonggang Qu, Chongyu Xu, Danni Li, Jiapeng Hu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuangyu He *Department of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110000, China.
Siqi Wen *Department of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110000, China.
Zhen WangThe Second Clinical College of China Medical University, Shenyang, Liaoning Province, 110000, China.
Yonggang QuThe Second Clinical College of China Medical University, Shenyang, Liaoning Province, 110000, China.
Chongyu XuDepartment of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110000, China.
Danni LiDepartment of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110000, China. cmu_danni_li@126.com.
Jiapeng HuDepartment of Pediatrics, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, 110000, China. jphu@cmu.edu.cn.

Funding

Doctoral Start-up Foundation of Liaoning Province 2024-BSLH-326National Natural Science Foundation of China 82200036
6 · The paper itself

Abstract

The ubiquitin-proteasome system (UPS) plays a crucial role in asthma by regulating protein stability And activity through post-translational modifications. This review provides a comprehensive Analysis of 42 UPS components in asthma, including one E2 ubiquitin-conjugating enzyme, 27 E3 ubiquitin ligases, eight deubiquitinating enzymes (DUBs), one dual-function (both E3 and DUB) enzyme, And five components of the 26S proteasome. Our Analysis focuses on four key pathological features, including airway inflammation, hyperresponsiveness, mucus hypersecretion, And remodeling. We identify 25 E3 ligase-substrate pairs and seven DUB-substrate pairs, detailing their ubiquitination and deubiquitination mechanisms. Additionally, a Literature review combined with GWAS data reveals 20 single-nucleotide polymorphisms (SNPs) across nine UPS Genes associated with asthma susceptibility. Therapeutic evaluations highlight 24 druggable UPS targets. Furthermore, we underscore 24 UPS-related compounds, with ten having established relevance to asthma And 14 exhibiting untapped potential. Emerging treatment strategies such as PROTACs and nanovaccines show promising potential. Overall, these findings provide new insights into UPS-mediated mechanisms and genetics in asthma and highlight its potential as a therapeutic target, paving the way for future research and clinical applications.

Indexed as

AsthmaProteasome Endopeptidase ComplexUbiquitinAnimalsDeubiquitinating EnzymesGenetic Predisposition to DiseaseHumansMolecular Targeted TherapyPolymorphism, Single NucleotideProtein Processing, Post-TranslationalUbiquitinationUbiquitin-Protein LigasesDeubiquitinating EnzymesProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein LigasesAsthmaSNPTherapeutic targetingUbiquitin–proteasome system

Identifiers

PMID40935955

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.